Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan

Published:2022-01-31 Issue:1 Volume:5 Page:e2145515
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Takumoto Yuki¹²,Sasahara Yuriko³,Narimatsu Hiroto⁴⁵⁶,Akazawa Manabu¹

Affiliation:

1. Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan

2. Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan

3. Department of Clinical Oncology, Yamagata Prefectural Central Hospital, Yamagata, Japan

4. Department of Genetic Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan

5. Cancer Prevention and Cancer Control Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan

6. Graduate School of Health Innovation, Kanagawa University of Human Services, Kawasaki, Kanagawa, Japan

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2788498/takumoto_2022_oi_211256_1643043091.84052.pdf

Reference52 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.;Ferlay;Int J Cancer,2015

2. Japan Pancreas Society, Pancreatic Cancer Registry Report of Japan 2007;Committee for Pancreatic Cancer Registry;J Jpn Pancreas Soc,2007

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.;Burris;J Clin Oncol,1997

4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.;Conroy;N Engl J Med,2011

5. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.;Von Hoff;N Engl J Med,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data;Journal of Clinical Medicine;2024-05-30

2. Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database;Pancreas;2024-05-16

3. Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis;Heliyon;2024-04

4. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer;JAMA Network Open;2024-01-08

5. Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis;American Journal of Cancer Research;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3